CIP
MRTX

Chartwell Investment Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Chartwell Investment Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9,143
Closed -$1.18M – 438
2019
Q4 		$1.18M Sell
9,143
-8,958
-49% -$864K 0.04% 344
2019
Q3 		$1.41M Hold
18,101
– – 0.05% 350
2019
Q2 		$1.86M Buy
+18,101
New +$1.41M 0.06% 329

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Chartwell Investment Partners's MRTX Position: Q1 2020 in Review

Chartwell Investment Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2020, closing a stake of 9,143 shares — an estimated $1.18M sold.

Chartwell Investment Partners first reported a position in MRTX in Q2 2019 and held it in 3 quarters. The position peaked at $1.86M in Q2 2019. 173 funds tracked by Wall St. Rank hold MRTX as of Q1 2020.

  • Chartwell Investment Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Chartwell Investment Partners sold 9,143 Mirati Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $1.18M.
  • Chartwell Investment Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Chartwell Investment Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $1.86M in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Chartwell Investment Partners's 13F filing for Q1 2020, filed 30 Apr 2020.